var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = ""; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })();

Blood products and related biologicals

Quality Assurance and Safety: Blood Products and related Biologicals

66顺彩票appSince the middle of the 20th century, medical science has found ways to prepare therapeutic products derived from human blood and plasma for the treatment of many life threatening diseases, as well as for complex surgical procedures.

Home page image

Processing blood into various types of medicines or products is a highly specialized process because blood products and biological technologies are inherently variable due to the nature of the source materials as well as the methods used to test them. The overall goal of the National Regulatory Authorities is to ensure that only blood products of demonstrated quality, safety and efficacy should be used. Yet, experience with regulatory authorities indicate that many countries have significant difficulties in fulfilling their responsibilities in this field.

WHO is responding to immediate needs by providing technical guidance and quality assurance tools to Medicines Regulatory Authorities, National Control Laboratories and manufacturers to support implementation of quality and safety systems for the production and control of blood products and related in vitro diagnostic devices worldwide.

The development of International Reference Materials and Guidelines to support the technical capacity of National Regulatory Authorities and to assure the compliance of manufacturers to quality and safety measures form the basis of our Mission. These contribute to technology transfer and global harmonization of quality assurance regulations.

66顺彩票appChallenges and Issues:

  • To strengthen National Regulatory Authorities on quality assurance systems for the control of quality and safety of blood products and in vitro diagnostic devices.
  • Need to assure quality and safety of blood and plasma globally to prevent transmission of blood-borne viral diseases via blood products.
  • Need to prioritize the development of WHO International Reference Materials of interest in Regions and countries with limited resources.
  • To facilitate access to and appropriate use of WHO International Reference Materials by national control laboratories or designated laboratories and manufacturers in developing countries.
  • To promote support for the implementation of new manufacturing technologies to avoid viral contamination and other infectious agents via blood products.

Related documents

Related links

963彩票开户 677彩票开户 7072彩票开户 66顺彩票总代理 7073彩票地址 689彩票邀请码 7073彩票网址 7073彩票登录 8炫彩彩票app 9188彩票代理